60–80%Metabolism Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, avapro or diovan cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced avapro or diovan is an angiotensin II receptor antagonists, irbesartan receptor.

number 138402-11-6ATC code C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 60–80%Metabolism Hepatic (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence avapro or diovan EU, USPregnancy cat. D (Au)Legal status S4 avapro or diovan POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now avapro or diovan of sanofi-aventis). It is jointly marketed by avapro or diovan and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with diuretic2 References3 See also[edit] Clinical useMain article: Angiotensin avapro or diovan receptor antagonists, irbesartan is indicated for the treatment of hypertension.

with nephropathy due avapro or diovan type 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID 11565517.^ Rossi PMID.